Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States.

By R. Bright, D. Shay, B. Shu, N. Cox, A. Klimov. Journal of the American Medical Association (JAMA), 2006

698 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Antiviral agents active against influenza A viruses (2006, background): “In particular, the incidence of adamantane resistance among influenza A (H3N2) viruses isolated in the United States 13 and worldwide 14 has been a cause for concern.”
Influenza (2018, background): “I nfluenza is a major concern forintensivists in all communities inthe United States.”
Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). (2011, background): “During the 2005–06 influenza season, CDC determined that 193 (92%) of 209 influenza A (H3N2) viruses isolated from patients in 26 states demonstrated a change at amino acid 31 in the M2 gene that confers resistance to adamantanes (138).”
Avian Influenza Virus (H5N1): a Threat to Human Health (2007, background): “Note that recent epidemic H3N2 strains have also acquired high levels of resistance to the adamantanes (17).”
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults (2007, background): “Oseltamivir and zan-amivir are both approved for prophylaxis; amantadine and ri-mantadine have FDA indications for chemoprophylaxis against inﬂuenza A infection, but these agents are currently not recommended because of the frequency of resistance among strains circulating in the United States and C”